Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cystic fibrosis
Biotech
Blackstone Invests $250M in Anagram to reduce CF pill burden
BLXS' $250 million investment in Anagram will advance an oral therapy expected to reduce the pill burden for exocrine pancreatic insufficiency.
Will Maddox
May 7, 2026 10:36am
Vertex drops Moderna-partnered inhaled CF candidate
May 4, 2026 5:48pm
Boehringer axes gene therapy after seeing cystic fibrosis data
Feb 17, 2026 1:12pm
Arcturus' stock halves on cystic fibrosis readout
Oct 22, 2025 1:01pm
Arcturus doubles down on mRNA, axes several early-stage assets
May 13, 2025 1:32pm
Vertex takes $379M hit tied to cancelled islet cell program
May 6, 2025 12:50pm
